Experimental Hematology
Volume 35, Issue 4 , Pages 618-626, April 2007

The role of Wilms' tumor gene peptide–specific cytotoxic T lymphocytes in immunologic selection of a paroxysmal nocturnal hemoglobinuria clone

  • Kazuhiko Ikeda

      Affiliations

    • First Department of Internal Medicine, Fukushima Medical University, Fukushima, Japan
  • ,
  • Tsutomu Shichishima

      Affiliations

    • First Department of Internal Medicine, Fukushima Medical University, Fukushima, Japan
    • Fukushima Research Institute of Environment and Medicine, Fukushima, Japan
    • Corresponding Author InformationOffprint requests to: Tsutomu Shichishima, M.D., Ph.D., First Department of Internal Medicine, Fukushima Medical University, 1 Hikariga-oka, Fukushima, Fukushima 960-1295, Japan
  • ,
  • Masaki Yasukawa

      Affiliations

    • First Department of Internal Medicine, Ehime University School of Medicine, Ehime, Japan
  • ,
  • Akiko Nakamura-Shichishima

      Affiliations

    • First Department of Internal Medicine, Fukushima Medical University, Fukushima, Japan
  • ,
  • Hideyoshi Noji

      Affiliations

    • First Department of Internal Medicine, Fukushima Medical University, Fukushima, Japan
  • ,
  • Kazuko Akutsu

      Affiliations

    • First Department of Internal Medicine, Fukushima Medical University, Fukushima, Japan
  • ,
  • Kazuoki Osumi

      Affiliations

    • Otsuka Life Science Initiative, Otsuka Pharmaceutical Initiative, Tokyo, Japan
  • ,
  • Yukio Maruyama

      Affiliations

    • First Department of Internal Medicine, Fukushima Medical University, Fukushima, Japan

Received 2 June 2006; received in revised form 29 December 2006; accepted 19 January 2007.

Objective

To clarify an expansion mechanism of a paroxysmal nocturnal hemoglobinuria (PNH) clone with the Wilms' tumor gene (WT1).

Materials and Methods

In PNH patients with the HLA-A2402 allele, frequencies of peripheral blood (PB) WT1 peptide–specific and HLA-A2402-restricted CD8+ cells and WT1 peptide–stimulated interferon-γ-producing mononuclear cells (MNCs), cytotoxicity of WT1 peptide–specific and HLA-A2402-restricted cytotoxic T lymphocyte (CTL) clone (TAK-1) cells on bone marrow (BM) MNCs, and after co-incubation with TAK-1 cells, changes in colony-forming unit granulocyte-macrophage colony formation of CD34+ cells and in CD59 expression in viable CD34+ cells were investigated.

Results

The frequencies of PB WT1 peptide–specific and HLA-A2402-restricted CD8+ cells (p < 0.005) and WT1 peptide–stimulated interferon-γ-producing MNCs (p < 0.02) were significantly higher in 5 PNH patients than 8 healthy volunteers (HV). In 5 PNH patients or 3 HV, TAK-1 cells significantly killed BMMNCs and suppressed colony formations of CD34+CD59+ and/or CD34+CD59 cells in the absence and presence of a WT1 peptide or only in the presence of the peptide, respectively, in an HLA-restricted manner. After co-incubation with TAK-1 cells, reduction rates of colony formation of CD34+CD59 cells were significantly less than those of CD34+CD59+ cells in 5 PNH patients (p < 0.002) and proportions of viable CD34+CD59 cells from 5 PNH patients significantly increased in the absence (p < 0.01) and presence (p < 0.01) of a WT1 peptide in an HLA-restricted manner.

Conclusion

WT1 peptide–specific and HLA-restricted CTLs may play an important role in expansion of a PNH clone during immunologic selection and/or in the occurrence of BM failure via interferon-γ in PNH.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0301-472X(07)00056-2

doi:10.1016/j.exphem.2007.01.045

Experimental Hematology
Volume 35, Issue 4 , Pages 618-626, April 2007